Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Mar 22;17:210. doi: 10.1186/s12885-017-3185-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 1 — Panel (A) shows plasma levels of H1047R PIK3CA mutation (%) on cfDNA quantified by dPCR and CEA (ng/ml) tumor marker across four time points (months) (Pearson correlation coefficient =0.92) from patient 2, PD = progressive disease. Panel (B) shows plasma levels of H1047R PIK3CA mutation (%) on cfDNA across four time points (months). Disease status as ascertained on a CT-scan at two time points is marked with a discontinuous line. The use of adryamicine based chemotherapy is indicated by gray shading. As shown, PIK3CA mutation quantification increased until October when the patient 44 was diagnosed as having a progressive disease (PD). Subsequently, the patient received a different line of palliative treatment. PIK3CA mutation significantly decreased from 2.08% (CI 1.768% – 2.429%) to 0.81% (0.487% – 1.342%) correlating with the partial response (PR) assessed by CT-scan. Panel (C) shows the plasma levels of tumor markers 15–3 (U/ml) and CEA (ng/ml) and CT-scans showing the bone metastasis, lung metastases and the axillary adenopathy from patient 31. In this case the H1047R mutation quantification went down to 0% over the course of treatment (from 0.19 to 0%) correlating with tumor markers, the visceral metastases (white arrow) and the adenopathies (circle) although the bone metastasis increased significantly in size (white arrow)